All news

About 120 patients in China live with an implanted neural interface

Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .

Invasive neural interfaces in China are moving from isolated experiments to paid clinical practice — which speeds up data accumulation for the next generations of BCIs.

Hong Bo, chief scientist at the Lingang laboratory, said that about 120 patients in China have been wearing an implanted brain interface for more than a month, and called 2026 the "year of clinical application" for Chinese BCIs. Neuracle's NEO system, approved by the NMPA in March 2026 as the world's first invasive BCI medical device cleared for sale, has already been prescribed under 12 commercial prescriptions; the epidural "Beinao-1" has passed 40 implantations and a full registration cohort, with documents planned for submission in 2027; StairMed has performed 42 long-term fully invasive implantations. More than 20 hospitals have opened BCI clinics, Shanghai's Hu Huibao program has included the Neuracle product, and a conference in Shanghai on December 3–6, 2026 is set to launch the formation of a national EEG data center. The figure of about 120 was obtained by summing across several teams and does not equal the number of commercial users.